BIOA

Conviction 27HealthcareScan · Mon, Aug 10, 2026

BIOA$11.47-2.18%

ResistanceSupportVol 14

Vol MA14 1.8M

May 11May 28Jun 16Jul 6Jul 23Aug 10

BioAge Labs, Inc.PHARMACEUTICAL PREPARATIONSwww.bioagelabs.com ↗

Price11.47

Change-2.18%

Gap-0.77%

Rel volume0.90×

Avg volume1.39M

Avg $ vol18.82M

SMA 2018.37

SMA 5019.70

SMA 20016.70

Price vs 50-41.81%

Price vs 200-31.34%

MA stackmixed

50/200 cross—

Supertrenddown · 17.88

RSI (14)33

MACD hist-1.08

MACD cross—

Stoch %K / %D17 / 17

ADX (14)32

+DI / −DI17 / 37

RSI divergence—

MACD divergence—

ATR %+17.90%

ADR %8.26%

52w high25.10

52w low4.33

From 52w high-54.32%

Above 52w low+164.78%

New 52w highNo

SqueezeOff

Bollinger width120.42%

%B0.19

Donchian pos17.31%

Donchian high24.91

Donchian low8.65

AVWAP (52w high)14.68

vs AVWAP high-21.89%

AVWAP (52w low)15.52

vs AVWAP low-26.12%

OBV trendDown

Chaikin MF (20)-0.03

Today vs 20d0.90×

Avg vol (14d)1.8M

Avg vol (20d)1.39M

Avg $ vol (20d)18.82M

Market cap526.21M

RS 3m (vs SPY)-39.93%

RS 6m (vs SPY)-55.46%

RS line new highNo

Trend template4/8

Technical rank9.3

1 week+6.35%

1 month-52.90%

3 months-36.27%

6 months-44.69%

1 year+165.39%

YTD-10.64%

P/E-6.53

P/B1.40

P/S58.50

P/FCF-6.39

EPS-2.24

Div yield—

ROE-21.50%

ROA-20.31%

Debt/Eq0.00

Current17.19

EV/EBITDA—

Gross margin—

Net margin-896.11%

Rev growth—

EPS growth-13.35%

Price target35.63

Target upside210.77%

Analyst ratingBuy

Institutional80.70%

Ent. value452.24M

Revenue2.45M

Net income-26.1M

Gross profit—

Free cash flow-82.35M

IndustryPHARMACEUTICAL PREPARATIONS

ExchangeNasdaq

Shares out44.45M

Employees62

ListedThu, Sep 26, 2024

Free float18.5M

Float %51.6%

Short interest2.45M

Days to cover4.5d

Short volume45.2%

Squeeze score53 / 100

Next earnings—

EPS forecast—

Last EPS vs est−$0.58 vs −$0.65

Last surprise+10.8% beat

Setup gradeD

Conviction27 / 100

Pattern quality—

Tech rank9.3 / 100

Group rank86 / 100 · Leading

Status laneNo active setup

Setup direction—

Pattern family

Resistance25.88

Support15.01

Days since event—

Candle confirm—

News sentiment—

Financials as of Tue, Jun 30, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in BIOA

All disclosures →

No recent disclosed trades by Congress in BIOA. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in BIOA · 1 buy · 1 sell

Insider	Side	Shares	Value	Traded	Filed
GOLDSTEIN DOV A MD Chief Financial Officer · Common Stock · 2026-04-23	Exercise	3.54K	$16K	2026-04-23	2026-04-24
GOLDSTEIN DOV A MD Chief Financial Officer · Stock Option (Right to Buy) · 2026-04-23	Exercise	3.54K	$0	2026-04-23	2026-04-24

SEC filings

EDGAR filings in BIOA · 5 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.